Pharmaceuticals

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Facing a crisis in patient access, Inizio unveils a next-gen hub using integrated analytics and pharmacy services to streamline the path to therapy.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

After nine years of success, a renewed pact between Novonesis and Biocodex aims to dominate the booming global probiotics market. Here's what it means.

The life sciences advisory firm adds a heavy-hitter with $150B+ in deal experience, signaling ambitious growth and a new focus on the Southeast.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

As its leaders vie for a top entrepreneurial award, a look at how GenScript quietly became an indispensable engine for global scientific breakthroughs.

A new peer-reviewed study shows MECART cleanrooms cut emissions by 33%, challenging industry standards with verifiable data and a circular design.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

The arrival of South Africa's first generic hormonal IUD aims to tackle high costs and low uptake of long-acting contraception in a nation of high unplanned pregnancies.

Hundreds of lupus advocates descended on Washington, demanding policy reform and research funding, and their persistent efforts are already yielding major results.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new state-of-the-art facility in Chicago aims to secure life-saving medicines, as GEODIS enters a heated race for pharmaceutical logistics dominance.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.